Plasma Thioredoxin Reductase as a Potential Biomarker for Gynecologic Cancer
Background According to previous literatures, plasma thioredoxin reductase (TrxR) level was significantly elevated in various malignant tumors and serve as a potential biomarker for diagnosis and prognostic prediction. However, there is little awareness of the clinical value of plasma TrxR in gyneco...
Main Authors: | Yinxing Zhu MS, Yixuan Hu MS, Junfeng Shi MD, Xiaowei Wei MD, Yaqi Song MD, Cuiju Tang MD, PhD, Wenwen Zhang MD, PhD |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2023-06-01
|
Series: | Technology in Cancer Research & Treatment |
Online Access: | https://doi.org/10.1177/15330338231184995 |
Similar Items
-
The American Board of Obstetrics and Gynecology's remote certifying examination: successes and challenges
by: Pooja Shivraj, MS, PhD, et al.
Published: (2022-11-01) -
Targeting thioredoxin reductase with organometallics
by: Koh, Wei Xiang
Published: (2021) -
Methylglyoxal Causes Dysfunction of Thioredoxin and Thioredoxin Reductase in Endothelial Cells
by: Ryosuke Tatsunami, et al.
Published: (2009-01-01) -
Clinical application of thioredoxin reductase as a novel biomarker in liver cancer
by: Xuping Wu, et al.
Published: (2021-03-01) -
Radical Extirpation With Intraoperative Radiotherapy for Locally Recurrent Gynecologic Cancer: An Institutional Review
by: Ritchie Delara, MD, et al.
Published: (2021-12-01)